Osteoporosis is a bone disorder characterized by
deficient bone mass and fragility fractures of the hip, wrist, and
spine. The therapeutic strategies for
treating osteoporosis are designed to maximize peak bone mass through
proper nutrition, appropriate intake of calcium and vitamin D,
maintenance of physiologic menstrual cycles, and a program of weight
bearing and strengthening exercises. For the conditions of high bone
turnover-- osteoporosis in which osteoclastic resorption is
increased--efficacious treatment options include hormone replacement
therapy, calcitonin, and bisphosphonates. Osteoporosis with low bone
turnover results from deficient osteoblastic bone formation and
responds to the experimental drug programs of fluoride, parathyroid
hormone, and parathyroid hormone related peptide analogues.
Determination of bone density defines the patient's current condition,
measurement of the level of N-telopeptides (collagen breakdown
products) predicts the patient's future regarding osteoporotic
fractures, and the presence of risk factors for hip fracture establish
the therapeutic window for treatment. (Lane JM. Spine."Osteoporosis.
Medical prevention and treatment". 1997 Dec 15;22(24 Suppl): 32S-37S).
Identified a tendency for some EDS patients to fracture, have low bone
mass and abnormal bone structure. The etiology is likely to be
mutifactorial, with an inherited structural element, accentuated by
immobility or reduced exercise." (Cabone L. et.al "Bone density in
Ehlers-Danlos Syndrome" Osteoporos Int. 2000, 11 (5): 388-92)